

Global Carrier Screening Market: Focus on Product Type, Technology Type, 18 Countries Data, Autosomal Recessive Disorders, Industry Insights, and Competitive Landscape – Analysis and Forecast, 2019-2029

<https://marketpublishers.com/r/GDACBF3DB692EN.html>

Date: June 2019

Pages: 181

Price: US\$ 5,000.00 (Single User License)

ID: GDACBF3DB692EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Key Questions Answered in this Report:

How the carrier screening market is expected to have an impact on the healthcare industry?

What was the total revenue generated by the global carrier screening market for autosomal recessive disorders in 2018 and how is it expected to grow during 2019 – 2029?

How are the transformational trends and major driving forces in this technology are expected to yield new business opportunities?

Which sub-segment of the global carrier screening market by disease, such as down syndrome, sickle cell anemia, cystic fibrosis, hemophilia, spinal muscular atrophy, fragile x syndrome, thalassemia, other autosomal recessive genetic disorders, during the forecast period, 2019-2029?

Which region, such as North America, Europe, Asia-Pacific, Latin-America is expected to grow the fastest in the global carrier screening market?

What are the key developmental strategies which are being implemented by the key players to stand out in this market?

Global Carrier Screening Market Forecast, 2019-2029

The global carrier screening Industry Analysis by BIS Research projects the market to grow with a double-digit compound annual growth rate between the years 2019 and 2029. The global carrier screening market was valued at \$846.9 million in 2018 and is estimated to grow over \$2.93 billion by 2029.

With substantial increase in the demand for carrier screening test and diagnostics tests based on sequencing, the carrier screening market is expected to witness an impressive growth and promises to be a lucrative field for investment.

Expert Quote on Global Carrier Screening Market

“North America is the leading contributor to the global carrier screening market and is noticed to be contributing more than 51.82% of the global market values. However, Asia-Pacific is expected to grow at an impressive 15.97% CAGR in the forecast period from 2019 to 2029. Currently, the Asia-Pacific market is estimated to contribute approximately 15.11% of total global market value.”

Scope of the Market Intelligent on the Global Carrier Screening Market

The purpose of this market analysis is to gain a holistic view of the carrier screening market in terms of various influencing factors, such as trends, technological advancements, and funding scenario in the market. The scope of this report constitutes of an in-depth study of the global carrier screening market, including a thorough analysis of the products across different regions.

Market Segmentation

The global carrier screening market is segmented on the basis of four sections, namely product, technology, disease type, and geography.

Under the global carrier screening market segmentation by product type, the laboratory developed tests sub-segment dominated the global carrier screening market in 2018. However, the NGS-based carrier screening test is expected to witness the highest

CAGR in the forecast period from 2019 to 2029.

Under the global carrier screening market segmentation by disease type, down syndrome currently dominates the global carrier screening market. Cystic fibrosis disease type is estimated to witness the highest CAGR in the forecast period.

The global carrier screening market segmentation by region is segregated under five major regions, such as North America, Europe, APAC, Latin America, and Rest-of-the-World. North America was the leading contributor of the global carrier screening market in 2018.

Key Companies in the Carrier Screening Market

The key players which have significant contributions to the carrier screening market include Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., Invitae Corporation, Eurofins Scientific, GenMark Diagnostics, 23and Me, Inc., Sema4, BGI, Centogene AG, Pathway Genomics, and Gene By Gene.

Contents

EXECUTIVE SUMMARY

1 MARKET OVERVIEW

2 MARKET DYNAMICS

2.1 Impact Analysis

2.2 Market Drivers

2.2.1 Availability of Advanced Screening Technologies

2.2.2 Shift of Reimbursement Policies Toward More Genetics Coverage

2.2.3 Increasing Prevalence of Genetic and Congenital disorders

2.2.4 Increasing Consumer Demand

2.3 Market Restraints

2.3.1 Limited Clinical Experience

2.3.2 General Public May Lack Interest in Expanded Carrier Screening

2.3.3 Technical Challenges of the Knowledge Base and Newer Sequencing Platforms

2.4 Market Opportunities

2.4.1 Genetic Counselling Needs to be Adapted for Expanded Carrier Screening Services

2.4.2 Availability of Direct-to-Consumer Tests

2.4.3 Capitalizing on the Potential Presented by the Emerging Markets of Asia

3 COMPETITIVE LANDSCAPE

3.1 Key Strategies and Developments

3.1.1 Collaborations, Partnerships, Joint Ventures, and Agreements

3.1.2 Business Expansion and Funding

3.1.3 Product Launch and Enhancements

3.1.4 Mergers and Acquisitions

3.2 Market Share Analysis

4 INDUSTRY INSIGHTS

4.1 Appropriate Use Criteria

4.1.1 Carrier Screening for Familial Disease

4.1.1.1 Fragile X

4.1.2 Carrier Screening for Common and Ethnic Genetic Diseases

- 4.1.2.1 Cystic Fibrosis
- 4.1.2.2 Spinal Muscular Atrophy
- 4.1.2.3 Hemoglobinopathies
- 4.1.2.4 Ashkenazi Jewish Carrier Screening
- 4.1.3 Other Ethnicities
- 4.2 American College of Obstetricians and Gynecologists (ACOG)
- 4.3 American College of Medical Genetics and Genomics (ACMG)
- 4.4 U.S. Food and Drug Administration (FDA)

5 GLOBAL CARRIER SCREENING MARKET (BY PRODUCT TYPE)

- 5.1 Laboratory Developed Tests (LDT)
- 5.2 Kits and Assays

6 GLOBAL CARRIER SCREENING MARKET (BY DISEASE)

- 6.1 Down Syndrome
- 6.2 Sickle Cell Anemia
- 6.3 Cystic Fibrosis
- 6.4 Hemophilia
- 6.5 Spinal Muscular Atrophy
- 6.6 Fragile X Syndrome
- 6.7 Thalassemia
- 6.8 Other Autosomal Recessive Genetic Disorders

7 GLOBAL CARRIER SCREENING MARKET (BY REGION)

- 7.1 North America
 - 7.1.1 North America: Market Dynamics
 - 7.1.2 North America Carrier Screening Market (by Country)
 - 7.1.2.1 U.S.
 - 7.1.2.2 Canada
- 7.2 Europe
 - 7.2.1 Europe: Market Dynamics
 - 7.2.2 Europe Carrier Screening Market (by Country)
 - 7.2.2.1 Germany
 - 7.2.2.2 U.K.
 - 7.2.2.3 France
 - 7.2.2.4 Italy

- 7.2.2.5 Spain
- 7.2.2.6 The Netherlands
- 7.2.2.7 Belgium
- 7.2.2.8 Switzerland
- 7.2.2.9 Denmark
- 7.2.2.10 Rest-of-Europe

7.3 Asia-Pacific

- 7.3.1 Asia-Pacific: Market Dynamics
- 7.3.2 Asia-Pacific, by Country
 - 7.3.2.1 China
 - 7.3.2.2 Japan
 - 7.3.2.3 Australia
 - 7.3.2.4 India
 - 7.3.2.5 South Korea
 - 7.3.2.6 Singapore
 - 7.3.2.7 Rest-of-the-Asia-Pacific

7.4 Latin America

- 7.4.1 Latin America: Market Dynamics
- 7.4.2 Latin America, by Country
 - 7.4.2.1 Brazil
 - 7.4.2.2 Mexico
 - 7.4.2.3 Rest-of-Latin America

7.5 Rest-of-the-World

8 COMPANY PROFILES

8.1 Overview

8.2 23andMe, Inc.

- 8.2.1 Company Overview
- 8.2.2 Role of 23andMe, Inc. in the Global Carrier Screening Market
- 8.2.3 SWOT Analysis

8.3 BGI

- 8.3.1 Company Overview
- 8.3.2 Role of BGI in the Global Carrier Screening Market
- 8.3.3 SWOT Analysis

8.4 CENTOGENE AG

- 8.4.1 Company Overview
- 8.4.2 Role of CENTOGENE AG in the Global Carrier Screening Market
- 8.4.3 SWOT Analysis

8.5 Eurofins Scientific

8.5.1 Company Overview

8.5.2 Role of Eurofins Scientific in the Global Carrier Screening Market

8.5.3 Financials

8.5.4 SWOT Analysis

8.6 Gene By Gene

8.6.1 Company Overview

8.6.2 Role of Gene By Gene in the Global Carrier Screening Market

8.6.3 SWOT Analysis

8.7 GenMark Diagnostics, Inc.

8.7.1 Company Overview

8.7.2 Role of GenMark Diagnostics, Inc. in the Global Carrier Screening Market

8.7.3 Financials

8.7.4 Key Insights about Financial Health of the Company

8.7.5 SWOT Analysis

8.8 Illumina, Inc.

8.8.1 Company Overview

8.8.2 Role of Illumina, Inc. in the Global Carrier Screening Market

8.8.3 Financials

8.8.4 Key Insights about Financial Health of the Company

8.8.5 SWOT Analysis

8.9 Invitae Corporation

8.9.1 Company Overview

8.9.2 Role of Invitae Corporation in the Global Carrier Screening Market

8.9.3 Financials

8.9.4 Key Insights about Financial Health of the Company

8.9.5 SWOT Analysis

8.10 Laboratory Corporation of America Holdings

8.10.1 Company Overview

8.10.2 Role of Laboratory Corporation of America Holdings in the Global Carrier Screening Market

8.10.3 Financials

8.10.4 SWOT Analysis

8.11 Myriad Genetics, Inc.

8.11.1 Company Overview

8.11.2 Role of Myriad Genetics, Inc. in the Global Carrier Screening Market

8.11.3 Financials

8.11.4 SWOT Analysis

8.12 Natera, Inc.

- 8.12.1 Company Overview
- 8.12.2 Role of Natera, Inc. in the Global Carrier Screening Market
- 8.12.3 Financials
 - 8.12.3.1 Key Insights of the Financial Health about the Company
- 8.12.4 SWOT Analysis
- 8.13 Pathway Genomics Corporation
 - 8.13.1 Company Overview
 - 8.13.2 Role of Pathway Genomics Corporation in the Global Carrier Screening Market
 - 8.13.3 SWOT Analysis
- 8.14 Quest Diagnostics Incorporated
 - 8.14.1 Company Overview
 - 8.14.2 Role of Quest Diagnostics Incorporated in the Global Carrier Screening Market
 - 8.14.3 Financials
 - 8.14.4 SWOT Analysis
- 8.15 Sema4
 - 8.15.1 Company Overview
 - 8.15.2 Role of Sema4 in the Global Carrier Screening Market
 - 8.15.3 SWOT Analysis
- 8.16 Thermo Fisher Scientific Inc.
 - 8.16.1 Company Overview
 - 8.16.2 Role of Thermo Fisher Scientific Inc. in the Global Carrier Screening Market
 - 8.16.3 Financials
 - 8.16.4 Key Insights about Financial Health of the Company
 - 8.16.5 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 2.1: Impact Analysis

Table 4.1: ACMG: American College of Medical Genetics and Genomics; ACOG: American College of Obstetricians and Gynecologists: Recommendations for Risk-Based Screening

Table 4.2: List of Regulatory Authorities involved in CLIA Program

Table 4.3: Regulatory Bodies

List Of Figures

LIST OF FIGURES

Figure 1: Drivers and Restraints of Carrier Screening Market

Figure 2: Key Strategies Incorporated by Stakeholders of Carrier Screening Market, to Sustain the Competition (from January 2015 to May 2019)

Figure 3: Global Carrier Screening Market, 2018-2029

Figure 4: Global Carrier Screening Market Share (by Product), 2018 and 2029

Figure 5: Global Carrier Screening LDT Market Share (by Technology), 2018 and 2029

Figure 6: Global Carrier Screening Market Share (by Disease Type), 2018 and 2029

Figure 7: Global Carrier Screening Market Share (by Region), 2018 and 2029

Figure 1.1: End-to-End Practice Workflow Support for Genetic Screening

Figure 1.2: Autosomal Recessive Inheritance of Harmful Mutations

Figure 1.3: The Journey to Expanded Carrier Screening

Figure 2.1: Market Dynamics of Global Carrier Screening Market

Figure 3.1: Competitive Landscape, January 2015-May 2019

Figure 3.2: Share of Key Developments and Strategies, January 2015-May 2019

Figure 3.3: Collaborations, Partnership, Joint Ventures, and Agreements Share (by Company), January 2015-May 2019

Figure 3.4: Business Expansion and Funding Share (by Company), January 2015-May 2019

Figure 3.5: Product Launches, Enhancements, Approvals, and Upgradation Share (by Company), January 2015-May 2019

Figure 3.6: Mergers and Acquisitions Share (by Company), January 2015-May 2019

Figure 3.7: Market Share Analysis (by Company) for the Global Carrier Screening Market, 2018

Figure 4.1: Classification of Tests in CLIA Program

Figure 5.1: Global carrier screening Market (by Product Type)

Figure 5.2: Global Carrier Screening Market (by Product Type), 2018 and 2029

Figure 5.3: Key players of Carrier Screening Test Market

Figure 5.4: Global Carrier Screening Test Market, 2018-2029

Figure 5.5: Global Carrier Screening Test Market (by Technology), 2018 and 2029, \$Million

Figure 5.6: Global Carrier Screening Laboratory Developed Test Market (NGS Technology), 2018-2029, \$Million

Figure 5.7: Global Carrier Screening Laboratory Developed Test Market (PCR Technology), 2018-2029, \$Million

Figure 5.8: Global Carrier Screening Laboratory Developed Test Market (Other

Technology), 2018-2029, \$Million

Figure 5.9: Key Players of the Kits and Assays Associated with Carrier Screening Market

Figure 5.10: Global Carrier Screening Kits and Assays Market, 2018-2029

Figure 6.1: Different Types of Autosomal Recessive Genetic Diseases

Figure 6.2: Global Carrier Screening Market (by Disease), 2018 and 2029

Figure 6.3: Global Carrier Screening Market (Down Syndrome), 2018-2029

Figure 6.4: Global Carrier Screening Market (Sickle Cell Anemia), 2018-2029

Figure 6.5: Global Carrier Screening Market (Cystic Fibrosis), 2018-2029

Figure 6.6: Global Carrier Screening Market (Hemophilia), 2018-2029

Figure 6.7: Global Carrier Screening Market (Spinal Muscular Atrophy), 2018-2029

Figure 6.8: Global Carrier Screening Market (Fragile X Syndrome), 2018-2029

Figure 6.9: Global Carrier Screening Market (Thalassemia), 2018-2029

Figure 6.10: Global Carrier Screening Market (Other Autosomal Recessive Genetic disorders), 2018-2029

Figure 7.1: Global Carrier Screening Market (by Region), 2019 and 2029

Figure 7.2: North America: Carrier Screening Market, (2018-2029)

Figure 7.3: North America: Market Dynamics

Figure 7.4: North America: Carrier Screening Market (by Country), 2018 and 2029

Figure 7.5: The U.S.: Carrier Screening Market, 2018-2029

Figure 7.6: Canada: Carrier Screening Market, 2018-2029

Figure 7.7: Europe: Carrier Screening Market (2018-2029)

Figure 7.8: Europe: Market Dynamics

Figure 7.9: Europe: Carrier Screening Market (by Country), 2018 and 2029

Figure 7.10: Germany: Carrier Screening Market (2018-2029)

Figure 7.11: U.K.: Carrier Screening Market, 2018-2029

Figure 7.12: France: Carrier Screening Market, 2018-2029

Figure 7.13: Italy: Carrier Screening Market, 2018-2029

Figure 7.14: Spain: Carrier Screening Market, 2018-2029

Figure 7.15: The Netherlands: Carrier Screening Market, 2018-2029

Figure 7.16: Belgium: Carrier Screening Market, 2018-2029

Figure 7.17: Switzerland: Carrier Screening Market, 2018-2029

Figure 7.18: Denmark: Carrier Screening Market, 2018-2029

Figure 7.19: Rest-of-Europe: Carrier Screening Market, 2018-2029

Figure 7.20: Asia-Pacific: Carrier Screening Market, (2018-2029)

Figure 7.21: Asia-Pacific: Market Dynamics

Figure 7.22: Asia-Pacific: Carrier Screening Market (by Country), 2018 and 2029

Figure 7.23: China: Carrier Screening Market, 2018-2029

Figure 7.24: Japan: Carrier Screening Market, 2018-2029

- Figure 7.25: Australia: Carrier Screening Market, 2018-2029
- Figure 7.26: India: Carrier Screening Market, 2018-2029
- Figure 7.27: South Korea: Carrier Screening Market, 2018-2029
- Figure 7.28: Singapore: Carrier Screening Market, 2018-2029
- Figure 7.29: Rest-of-the-Asia-Pacific: Carrier Screening Market, 2018-2029
- Figure 7.30: Latin America: Carrier Screening Market, (2018-2029)
- Figure 7.31: Latin America: Market Dynamics
- Figure 7.32: Latin America: Carrier Screening Market (by Country), 2018 and 2029
- Figure 7.33: Brazil: Carrier Screening Market, 2018-2029
- Figure 7.34: Mexico: Carrier Screening Market, 2018-2029
- Figure 7.35: Rest-of-Latin America: Carrier Screening Market, 2018-2029
- Figure 7.36: Rest-of-the-World: Carrier Screening Market, 2018-2029
- Figure 8.1: Shares of Key Company Profiles
- Figure 8.2: 23and Me, Inc.: Overall Product Portfolio
- Figure 8.3: 23andMe Inc.: SWOT Analysis
- Figure 8.4: BGI Product Offerings for Global Carrier Screening Market
- Figure 8.5: BGI: SWOT Analysis
- Figure 8.6: CENTOGENE AG: Overall Product Portfolio
- Figure 8.7: CENTOGENE AG: SWOT Analysis
- Figure 8.8: Eurofins Scientific: Overall Product Portfolio
- Figure 8.9: Eurofins Scientific: Overall Financials, 2016-2018
- Figure 8.10: Eurofins Scientific: Revenue (by Region), 2016-2018
- Figure 8.11: Eurofins Scientific: SWOT Analysis
- Figure 8.12: Gene by Gene: Overall Product Portfolio
- Figure 8.13: Gene By Gene: SWOT Analysis
- Figure 8.14: GenMark Diagnostics, Inc.: Overall Product Portfolio
- Figure 8.15: GenMark Diagnostics, Inc.: Overall Financials, 2016-2018
- Figure 8.16: GenMark Diagnostics, Inc.: R&D Expenditure, 2016-2018
- Figure 8.17: GenMark Diagnostics, Inc.: SWOT Analysis
- Figure 8.18: Illumina, Inc.: Overall Product Portfolio
- Figure 8.19: Illumina, Inc.: Overall Financials, 2016-2018
- Figure 8.20: Illumina, Inc.: Revenue (by Segment), 2016-2018
- Figure 8.21: Illumina, Inc.: Revenue (by Region), 2016-2018
- Figure 8.22: Illumina, Inc.: R&D Expenditure, 2016-2018
- Figure 8.23: Illumina, Inc.: SWOT Analysis
- Figure 8.24: Invitae Corporation: Overall Product Portfolio
- Figure 8.25: Invitae Corporation: Overall Financials, 2016-2018
- Figure 8.26: Invitae Corporation: Revenue (by Region), 2016-2018
- Figure 8.27: Invitae Corporation: R&D Expenditure, 2016-2018

- Figure 8.28: Invitae Corporation: SWOT Analysis
- Figure 8.29: Laboratory Corporation of America Holdings: Overall Product Portfolio
- Figure 8.30: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
- Figure 8.31: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
- Figure 8.32: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
- Figure 8.33: Laboratory Corporation of America Holdings: SWOT Analysis
- Figure 8.34: Myriad Genetics, Inc.: Overall Product Portfolio
- Figure 8.35: Myriad Genetics, Inc.: Overall Financials, 2016-2018
- Figure 8.36: Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
- Figure 8.37: Myriad Genetics, Inc.: SWOT Analysis
- Figure 8.38: Natera, Inc.: Overall Product Portfolio
- Figure 8.39: Natera, Inc.: Overall Financials, 2016-2018
- Figure 8.40: Natera, Inc.: Revenue (by Business Segment), 2016-2018
- Figure 8.41: Natera, Inc.: R&D Expense, 2016-2018
- Figure 8.42: Natera, Inc.: SWOT Analysis
- Figure 8.43: Pathway Genomics Corporation: Overall Product Portfolio
- Figure 8.44: Pathway Genomics Corporation: SWOT Analysis
- Figure 8.45: Product Portfolio: Quest Diagnostics Incorporated
- Figure 8.46: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
- Figure 8.47: Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
- Figure 8.48: Quest Diagnostics Incorporated: SWOT Analysis
- Figure 8.49: Sema4: Overall Product Portfolio
- Figure 8.50: Sema4: SWOT Analysis
- Figure 8.51: Thermo Fisher Scientific Inc.: Overall Product Portfolio
- Figure 8.52: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
- Figure 8.53: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
- Figure 8.54: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
- Figure 8.55: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
- Figure 8.56: Thermo Fisher Scientific Inc.: SWOT Analysis

I would like to order

Product name: Global Carrier Screening Market: Focus on Product Type, Technology Type, 18 Countries Data, Autosomal Recessive Disorders, Industry Insights, and Competitive Landscape – Analysis and Forecast, 2019-2029

Product link: <https://marketpublishers.com/r/GDACBF3DB692EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDACBF3DB692EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970